{"id":"W3024665518","doi":"10.1016/j.clgc.2020.05.004","title":"Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Takeda Canada; Eisai; Astellas Pharma; British Microcirculation Society; Merck Sharp and Dohme; Janssen Biotech; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Ipsen; Pharmacyclics; Astellas Pharma Canada; Sanofi España; Sanofi; GlaxoSmithKline Japan; Boehringer Ingelheim; Roche; Novartis; Bayer; University of Bristol; Merck; Novartis Farmacéutica; Ipsen Biopharmaceuticals; Bristol-Myers Squibb; AstraZeneca; Pfizer; Takeda Pharmaceutical Company","keywords":"Medicine; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Internal medicine; Urothelial cancer; Overall survival; Cancer; Bladder cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00548612,0.001046315,0.0025114,0.0005466249,0.000291242,0.001268495,0.0008389518,0.0008466049,0.00141047],"category_scores_gemma":[0.002616276,0.0003630832,0.004192215,0.0005739828,0.0005119648,0.0008344129,0.0007239836,0.001672565,0.0002049489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009506856,"about_ca_system_score_gemma":0.001241032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001865171,"about_ca_topic_score_gemma":0.004619634,"domain_scores_codex":[0.9984788,0.001061452,0.00005802342,0.0001496015,0.00009363412,0.0001584347],"domain_scores_gemma":[0.9985371,0.0005493223,0.0002325373,0.0001596619,0.00008988482,0.0004315022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8300577,0.002743216,0.07677034,0.0009784065,0.01428808,0.0001289963,0.0002172219,0.008059281,0.007199574,0.0003218891,0.004699727,0.05453565],"study_design_scores_gemma":[0.2053214,0.2138057,0.5316792,0.0002981613,0.02720168,0.0004267064,0.0003529279,0.009695917,0.003097642,0.001014726,0.006962227,0.0001436699],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916897,0.004631096,0.0003111858,0.0002478494,0.00008362881,0.0001503188,0.002096882,0.00002847754,0.0007608657],"genre_scores_gemma":[0.9926262,0.0009089966,0.0004440321,0.0003123924,0.00006797093,0.0001455854,0.004886247,0.00003700919,0.0005715571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00548612,"threshold_uncertainty_score":0.02901369,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08429556182043416,"score_gpt":0.4056710853970565,"score_spread":0.3213755235766224,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}